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Evaluation of a Novel Biomaterial in the Suprachoroidal
Space of the Rabbit Eye
Suzanne Einmahl,1,2 Michelle Savoldelli,3 Franc¸ois D’Hermies,3 Cyrus Tabatabay,1
Robert Gurny,1 and Francine Behar-Cohen2,3
PURPOSE. Drug delivery to treat diseases of the posterior seg-
ment of the eye, such as choroidal neovascularization and its
complications, is hampered by poor intraocular penetration
and rapid elimination of the drug from the eye. The purpose of
this study was to investigate the feasibility and tolerance of
suprachoroidal injections of poly(ortho ester) (POE), a bio-
erodible and biocompatible polymer, as a biomaterial poten-
tially useful for development of sustained drug delivery sys-
tems.
METHODS. After tunnelization of the sclera, different formula-
tions based on POE were injected (100 L) into the supracho-
roidal space of pigmented rabbits and compared with 1%
sodium hyaluronate. Follow-up consisted of fundus observa-
tions, echography, fluorescein angiography, and histologic
analysis over 3 weeks.
RESULTS. After injection, POE spread in the suprachoroidal
space at the posterior pole. It was well tolerated and progres-
sively disappeared from the site of injection without sequelae.
No bleeding or retinal detachment occurred. Echographic pic-
tures showed that the material was present in the supracho-
roidal space for 3 weeks. Angiography revealed minor pigment
irregularities at the site of injection, but no retinal edema or
necrosis. Histology showed that POE was well tolerated in the
choroid.
CONCLUSIONS. POE suprachoroidal injections, an easy, control-
lable, and reproducible procedure, were well tolerated in the
rabbit eye. POE appears to be a promising biomaterial to
deliver drugs focally to the choroid and the retina. (Invest
Ophthalmol Vis Sci. 2002;43:1533–1539)
The delivery of therapeutic amounts of drugs to the tissuesof the posterior segment of the eye with reduced systemic
side effects remains a challenge, notably for the treatment of
exudative age-related macular degeneration (AMD).1 Choroidal
neovascularization (CNV) occurs at the site of an alteration of
the retinal pigment epithelium (RPE) and the Bruch mem-
brane, although the exact pathogenic mechanisms are not yet
understood.2 These alterations involve migration, proliferation,
and differentiation of microvascular endothelial cells and result
in the formation of an abnormal capillary network. A possible
approach for treating CNV is the delivery of antiangiogenic
drugs, which would specifically target the formation of new
vessels in the choroid.3–7 Another treatment strategy is the
administration of a neurotrophic drug that would help RPE
migration and proliferation after surgical ablation of CNV mem-
branes, to repopulate the atrophic zones of the retina in the
region of the excised neovessel.8
Unfortunately, the delivery of drugs to the posterior seg-
ment is frequently limited by the difficulty in targeting the
choroidal or retinal tissues. Systemic administration often leads
to insufficient concentration in tissues and is associated with
numerous side effects.9 Direct drug injections in the supracho-
roidal space would presumably allow therapeutic and nontoxic
drug concentrations to be achieved in the choroid and RPE.
However, if the drug is injected as a solution, it spreads in the
whole area in the suprachoroidal space, possibly resulting in
toxicity to surrounding tissues. Moreover, substances are elim-
inated rapidly through the choroidal blood flow.10 To circum-
vent these problems, it would be helpful to administer sus-
tained drug delivery systems locally, to increase site specificity,
to reduce side effects in the surrounding tissues, and to pro-
long delivery time.
Recent advances in biomaterials science has led to the
discovery of polymers offering controlled-release characteris-
tics. Among them, poly(ortho esters) (POEs) are a family of
hydrophobic, biocompatible,11 and bioerodible polymers.
POE’s bioresorption represents a significant advantage over
other nonbiodegradable drug delivery systems, because there
is no need to explant POE once all the drug has been released.
This ointmentlike material allows the incorporation of drugs
into the polymer by simple mixing at room temperature, with-
out the use of heat or solvents. As a consequence, fragile drugs,
such as proteins or oligonucleotides, can be delivered from this
polymer.12 POE is viscous and can be injected with a conven-
tional syringe through an appropriate needle. This nontrau-
matic procedure is clearly preferable to implantation of solid
devices, which requires a trocar or a complex surgical proce-
dure.
Kinetics of drug release from POE are constant and linear,
without burst effect, and can be controlled by many factors,
such as the polymer’s molecular weight or physicochemical
characteristics of the substances incorporated in the polymer
matrix. Notably, basic products prolong the polymer’s lifetime
by stabilizing the chemical backbone and slow down polymer
degradation13 and the drug release rate.14,15
Intraocular biocompatibility of aseptic POE has been as-
sessed in subconjunctival,16 intracameral,11 and intravitreal11
sites in the eye. In all cases, the polymer is well tolerated,
triggering a limited reversible acute inflammatory reaction but
no chronic inflammation or fibrotic encapsulation. Recently,
POE has also been evaluated as a carrier to deliver 5-fluorou-
racil in an animal model of filtering surgery. The sustained
release of the antiproliferative drug allows significant reduction
of intraocular pressure over an extended period, while reduc-
ing 5-fluorouracil’s corneal toxicity.17
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The purpose of this study was to investigate the feasibility
and biocompatibility of suprachoroidal injections of POE as a
potential drug delivery system for the posterior segment of the
eye.
MATERIALS AND METHODS
Polymer Synthesis and Characterization
POE was synthesized by a transesterification reaction between 1,2,6-
hexanetriol and trimethyl orthoacetate (Aldrich Chemie, Steinheim,
Germany) under anhydrous and aseptic conditions.18 POE was further
purified by a precipitation procedure to remove impurities, such as
residual monomers and oligomers.19,20
The polymer has been characterized by infrared spectroscopy,
nuclear magnetic resonance, and size-exclusion chromatography.21
The average molecular weight of the sterile polymer used in this study
was 10,000, with a polydispersity of 1.35. POE is a transparent, viscous
material, gel-like in appearance, with a refractive index of 1.47. It
shows Newtonian rheological behavior.
Preparation of the Formulations
Different formulations were tested: sodium hyaluronate 1% as a control
(Healon; Pharmacia Ophthalmics, Monrovia, CA), POE alone, POE with
1% (wt/wt) magnesium hydroxide (MG; Sigma Chemie AG, Buchs,
Switzerland), and POE with 1% (wt/wt) dexamethasone sodium phos-
phate (DEX; Sigma Chemie). MG was chosen as an excipient modulator
of POE degradation, because of its basic characteristics.13 DEX was
selected as a model anti-inflammatory and antiangiogenic drug.22 More-
over, the sodium phosphate salt of DEX is a basic substance, which also
modulates POE’s degradation rate and prolongs its lifetime.11,15,23
The formulations were prepared under a laminar air-flow hood. The
added substances had been -sterilized at 2.0 Mrad and homogeneously
dispersed in the aseptically prepared semisolid POE under aseptic
conditions at a concentration of 1% (wt/wt). The viscous mixture was
then loaded into a 1.0-mL hypodermic syringe, each sample being
100 L (120 mg).
Animals
Pigmented Fauve de Bourgogne female rabbits weighing from 2 to
3 kg, 10 to 12 weeks of age, were used in this study (Jean-Pierre Ravaut;
Institute of Agricultural Research, Nouzilly, France), and experiments
were conducted in accordance with the ARVO Statement for the Use
of Animals in Ophthalmic and Vision Research. Six eyes of six animals
were studied for each group.
Suprachoroidal Injection
The rabbits were sedated with 2 mg/kg intramuscular midazolam, and
general anesthesia was induced with intramuscular injection of
50 mg/kg ketamine and 15 mg/kg xylazine. Pupils were dilated with
topical 10% phenylephrine and 0.5% tropicamide, instilled every 10
minutes, beginning 1 hour before surgery. With rabbits under local
anesthesia with oxybuprocaine 0.4% (Novesine; Ciba Vision, Basel,
Switzerland), a lid speculum was placed. The conjunctiva and Tenon
capsule were opened in the upper temporal quadrant, as appropriate
for the extent of the procedure. A small (2-mm) full-thickness scleral
incision was performed parallel to and 5 mm from the limbus. A 5- to
6-mm-long tunnelization of the sclera was made with microsurgical
scissors to separate the sclera from the choroid and reveal the supra-
choroidal space. A curved cannula with an olivary tip (0.6 mm of
internal diameter) was introduced into the suprachoroidal space and
advanced toward the posterior pole (Fig. 1). Each formulation was
injected with an injection volume of 100 L. The needle tip was
apposed to the inner wall of the sclera to avoid contact with the
choroid. No reflux of material was observed through the sclerotomy.
The scleral incision was sutured by 8-0 silk sutures. The conjunctiva
was finally closed with 8-0 Vicryl sutures (Ethicon, Piscataway, NJ), and
topical neomycin ointment was applied. The entire operation was
FIGURE 1. Injection of POE into the suprachoroidal space.
FIGURE 2. Fundus photograph on postoperative day 6, showing alter-
ations in pigmentation after suprachoroidal POE injection (arrow).
FIGURE 3. Macroscopic view of an enucleated eye on postoperative
day 7, showing the fundus with pigment alteration () and fragmented
POE appearing as whitish spots (arrow).
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observed and controlled under an operating microscope. The location
of the injection was then noted with indirect ophthalmoscopy.
Clinical Follow-up
Rabbits were examined at regular intervals up to 3 weeks after surgery.
Slit lamp observations were performed to assess the inflammatory state
of the eye, with particular attention to the conjunctiva, the sclera, and
the vitreous. Clinical signs of posterior inflammation were scored as
follows: grade 0, clear vitreous cavity; grade 1, vitreous Tyndall, min-
imal fibrin exudate; grade 2, significant fibrin exudate; and grade 3,
opaque vitreous hindering the examination of the fundus. Statistical
analysis was performed to compare posterior inflammation between
experimental and control eyes, using a nonparametric Mann-Whitney
test. P  0.05 was considered significant.
The fundus was regularly observed by indirect ophthalmoscopy.
Photographs of the fundus were taken with a retinograph specially
designed for small animals (Kowa Genesis; Luneau, Chartres, France).
Intraocular pressure was measured by Goldmann applanation tonom-
etry.
Ultrasound echography (Alcon, Fort Worth, TX) was performed at
regular intervals to visualize POE localization in the suprachoroidal
space. Ultrasonography was repeated until the polymer had totally
disappeared.
A 10% fluorescein solution (Faure, Annonay, France) was injected
intravenously with an injection volume of 0.5 mL. Fluorescein angio-
grams were performed with a fundus camera (SL6E; Topcon, Tokyo,
Japan). Fluorescein angiography was performed at determined times
after surgery to detect any consequence resulting from the presence of
the polymer in the suprachoroidal space, such as leakage in the
vascular bed of the choroid or the retina.
Histologic Analysis
Rabbits were killed at days 5, 12, and 20 after the procedure by
intracardiac injection of a lethal dose of pentobarbital. Their eyes were
enucleated, dissected, observed macroscopically, and photographed.
Tissues were then fixed to be studied histologically.
The sclera, choroid, and retina were fixed for 2 hours in 2.5%
glutaraldehyde in cacodylate buffer after careful orientation of the
samples with respect to the polarity (center to periphery). Samples
were then further processed in 0.1 M cacodylate buffer (pH 7.3), after
fixing in osmium epoxide and embedding in LX 112 resin (Ladd,
Burlington, VT). Subsequent semithin sections were obtained using an
ultramicrotome and counterstained with toluidine blue. Semithin sec-
tions were analyzed using photonic microscopy and polarization.
Transmission Electron Microscopy
Ultrathin sections of the regions of interest were obtained for all
samples, by cutting with an ultramicrotome, and counterstained with
uranyl acetate and lead citrate. The sections were observed with a
transmission electron microscope (CM10; Philips Electronics NV, Eind-
hoven, The Netherlands).
RESULTS
Clinical Observations
Immediately after injection, the polymer spread in a limited
area of the suprachoroidal space at the extremity of the created
tunnel, triggering some visible elevation of the retina and
choroid on clinical observation. Twenty-four hours after sur-
gery, POE spread in a larger and thinner area in the supracho-
roidal space. No subretinal or choroidal hemorrhage or any
retinal lesions were caused by the suprachoroidal injection. No
vitreal Tyndall or retinal edema was observed at or around the
location of polymer nor did any substance enter the subretinal
space. All eyes were quiet, with no evidence of immediate or
delayed intraocular inflammation. The grade of anterior and
posterior inflammation was 0 for all eyes. Slight conjunctival
hyperemia was observed, associated with the conjunctival in-
cision. When the sclera was depressed, a depigmented zone of
choroid was observed at the site of the scleral incision, as seen
at the sclerotomy site during vitrectomy.
The only mild change noted in the appearance of the fun-
dus was a minimal, stripelike alteration of the pigmentation in
the region of the injected polymer, noted from postoperative
day 1 (Fig. 2). These irregularities seemed to be due to a
pigment redistribution in the choroidal melanosomes rather
than to an alteration of the RPE cells, as later confirmed by
histology. No significant increase in postoperative intraocular
pressure or shallowing of the anterior chamber was noted.
Macroscopic examination of the dissected eyes showed that
polymer was fragmented into small, whitish bubbles (Fig. 3),
which may be explained by a random degradation of the
FIGURE 4. Fundus photograph on postoperative day 5, showing local
retinal atrophy after suprachoroidal sodium hyaluronate injection (ar-
row).
FIGURE 5. Echographic images on
postoperative day 5, showing (A) a
normal rabbit eye and (B) POE in
the suprachoroidal space (hypoecho-
genic zone, arrow).
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polymer compressed to a thin film between the choroid and
the sclera.
POE remained present in the suprachoroidal space for ap-
proximately 3 weeks. No significant differences could be noted
between various experimental groups of POE, all of which
appeared on clinical observation to have tolerated the treat-
ment well. The control group having received sodium hyaluro-
nate (Healon; Pharmacia Ophthalmics) exhibited a limited
zone of choroidal atrophy, as shown in Figure 4.
Ultrasonography
Ultrasonography was performed on regular days after surgery
to observe POE and its bioresorption from the suprachoroidal
site, and results were compared with preoperative echographs
(Fig. 5A). POE was clearly observed as a hypoechogenic sub-
stance in the suprachoroidal space, without triggering any
choroidal detachment or hematoma (Fig. 5B). Indeed, no liquid
accumulation was observed around the polymer. No retinal
detachment was detected echographically at any place.
By echographic examinations, it was noted that the dark
zone corresponding to the polymer in the suprachoroidal
space passably thinned with time, with a total resorption at the
end of the experiment, 3 weeks after surgery.
Fluorescein Angiography
Angiography was first performed in normal rabbit eyes (Fig.
6A) and then at regular intervals after surgery in experimental
eyes. In the prearterial phase of the angiogram, the choroidal
filling showed a limited alteration of choroidal coloration with
punctuate mask effect, but no destruction or detachment of
the RPE, which would have caused a window effect or a
subretinal leakage of the dye. The arterial and venous phases
appeared normal and no late hyperfluorescence was observed,
showing that the retinal vasculature’s permeability was not
altered. The choroidal pigment alterations remained stable
during the angiographic sequence and were localized at the
temporosuperior side of the optic disc, where the polymer had
been injected (Fig. 6B). The POE itself was not visible; how-
ever, the observed scattered masking effect indicated that POE
was partly located in the suprachoroidal space, partly in the
choroid.
Angiograms were further performed at 1 and 2 weeks after
the injection and did not show any changes with time. These
results show that no retinal damage resulted from the supra-
choroidal presence of 100 L of POE or of its degradation
products.
Histology
In the area of injection, histologic examination revealed vari-
able changes, depending on which formulation was introduced
within the tissues. Eyes receiving sodium hyaluronate exhib-
ited a marked disorganization of the architecture and pigmen-
tation of the external retinal layers, with a focal loss of RPE,
associated with a thickening vacuolization of external articles
of the surrounding retina (Fig. 7). After the injection, small and
contiguous vacuoles of sodium hyaluronate were observed in
the choroid, along with a partial vacuolization of RPE cells,
whose shape appeared irregular.
In eyes receiving POE, whether alone or containing MG or
DEX, histologic examination of the tissues in the region of the
injection showed vacuoles of variable size in the suprachoroi-
FIGURE 6. Fluorescein angiographic
sequence on postoperative day 5,
showing (A) a normal rabbit eye and
(B) choroidal pigment alterations at
the site of polymer injection (ar-
row).
FIGURE 7. Semithin histologic section on postoperative day 5 of an
eye injected with sodium hyaluronate in the suprachoroidal space.
Toluidine blue; magnification, 250.
FIGURE 8. Semithin histologic section on postoperative day 19 of an
eye injected with POE containing DEX, showing POE-filled vacuoles
(arrows). Toluidine blue; magnification 150.
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dal space and in the choroid, involving the external layers, for
larger vacuoles, and the inner layers, for smaller vacuoles, next
to the Bruch membrane (Fig. 8).
The vacuoles, empty or apparently filled with some mate-
rial, possibly POE, mostly appeared in giant choroidal mela-
nophages whose pigment showed a degree of redistribution.
The phagocytic nature of these vacuoles was confirmed by
transmission electron microscopy (Fig. 9A). No inflammatory
cell infiltration was observed in the area of the POE injection at
any time. Overlying the region of vacuoles, a thinned choroid
and intact neuroretina were observed, without any inflamma-
tory reaction. No major retinal disorganization of the main
inner membranes of the eye was observed (Fig. 9B). Some
small vacuoles also appeared in the endothelial cells of the
choroidal vessels, and some were found in the choriocapillar-
ies.
DISCUSSION
The ideal material for a suprachoroidal implantation should
have the following properties: It should be injectable, to sim-
plify the implantation procedure, yet viscous enough to be
retained in the suprachoroidal space and deliver drugs locally.
It should be immunologically inert and provoke no inflamma-
tory reaction or foreign body response. Eventually, it should be
degradable within an appropriate time to release the drug long
enough to treat the neovascularization and should disappear
from the injection site by complete bioresorption without
sequelae. This study reports the suprachoroidal injection of a
particularly good candidate that fulfills these conditions—a
biocompatible, injectable, and bioerodible material, POE.
No difficulty was experienced in injecting 100 L POE into
the suprachoroidal space, the procedure being controllable by
eye, nontraumatic, and reproducible.
Suprachoroidal injections of POE were well tolerated in the
rabbit eye and caused no clinical complications; only a slight
stripelike anomaly of the choroidal pigmentation was ob-
served. This disturbance of the pigmentation occurs with other
biomaterials, as reported after suprachoroidal implantation of a
swelling urethane-based hydrophilic polymer.24 In that study,
the urethane polymer triggered a total loss of the pigment over
the implant, so that a clear view of the sclera could be ob-
tained. Such a complication was not observed in our study, in
which the pigment redistribution was minimal. It has also to be
emphasized that the control group (i.e., eyes receiving a so-
dium hyaluronate injection), exhibited some atrophy of the
RPE, which was not observed in the experimental POE groups.
The injection of 100 L POE triggered no visible choroidal
detachment. The suprachoroidal space is a virtual space,
bounded anteriorly by the scleral spur and posteriorly by the
optic nerve, with increased adhesion at the site of vortex veins
and posterior ciliary arteries. The choroid is grossly elastic,
with a good tensile strength, allowing moderate distension by
injection into the suprachoroidal space. By ultrasonography,
the polymer was located between the sclera and the choroid,
triggering no bulge and limited spreading in the suprachoroidal
space. This indicates that a focal drug release can potentially be
achieved with this delivery system. Several investigators have
reported a sharp, well-defined choroidal elevation after supra-
choroidal injection of larger volumes (300 L) of products
such as sodium hyaluronate,25,26 but in those studies, choroi-
dal detachment reabsorbed without sequelae, which suggests
that localized temporary distension of the suprachoroidal
space with a biologically compatible material is a generally
benign event.
After angiography, it was possible to conclude that the
retinal and choroidal vasculature were not affected by the
presence of 100 L POE. The RPE cells were apparently intact,
because no window effect was observed. A scattered masking
effect indicated that POE was apparently located both in the
suprachoroidal space and in the choroid itself. This was later
confirmed by histopathologic analysis. Therefore, angiography
allowed indirect confirmation of the localization of POE, at the
temporoposterior pole of the median raphe.
Concerning the histologic reactions, no significant disorga-
nization of the retina was observed in the experimental POE
groups. Vacuoles were observed in the choroid and in the
suprachoroidal space, and were close to the Bruch membrane.
A favored hypothesis regarding the presence of these vacuoles
consists in the possible phagocytosis of fragmented, randomly
degraded POE by melanophages that had fused between each
other and presented minor and inconsequential pigment redis-
tribution. Giant, fused melanocytes have been observed in
rabbit eyes after the implantation of stainless steel pieces.27
FIGURE 9. Transmission electron mi-
crograph on postoperative day 19 of
an eye injected with POE containing
DEX. (A) Melanophage with vacuoles
containing POE (arrows). (B) Nor-
mal retina overlaying the site of POE
injection. Magnification: (A) 6600;
(B) 2880.
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The changes observed in our study were significantly minor
compared with those described by Foulds et al.24 after implan-
tation of the urethane-based hydrophilic polymer. In this par-
ticular case, a striking mononuclear macrophagic response to
the polymer was observed, with adjacent fibrosis in the cho-
roid and chorioretinal fusion. In some specimens, choroidal
fibrosis lead to total retinal atrophy, whereas in others there
was reactionary proliferation of atrophic RPE cells.
Some vacuoles were also observed in the endothelium of
the choroidal vasculature, which appears interesting for treat-
ment of neovascularization. No inflammatory cell infiltration
was observed at any time. No significant differences were
found between the various POE groups in tissue biocompat-
ibility.
Sodium hyaluronate has been used in the suprachoroidal
space as a treatment for internal scleral buckling in cases of
retinal detachment, without triggering any toxic or inflamma-
tory reaction.25,26 In our experiments, sodium hyaluronate
alone was found to cause more retinal atrophy than was ob-
served after POE injection. There is no apparent reason for
such toxicity; however, an explanation may be found in the
injection procedure. Indeed, sodium hyaluronate is very fluid;
the injection flow was rapid and turbulent, which may have
disturbed the organization of the retina around the site of
injection. POE, on the contrary, is very viscous and therefore it
was injected slowly and smoothly, thus preventing any me-
chanical disturbance of the surrounding tissues.
Today, antiangiogenic molecules have been assayed in can-
cer therapy.28 Their local delivery at the site of choroidal
neovascularization would enable specific control of the growth
of new vessels without undesirable systemic side effects. How-
ever, targeting the recurrent subretinal vessels remains a major
difficulty. Hence, local, direct drug delivery is clearly prefera-
ble, through focal suprachoroidal administration, for example,
near the macular area. The drug will then diffuse in a con-
trolled and constant manner onto the macula, without trigger-
ing toxic effects in surrounding regions of the posterior seg-
ment. Because the blood flow in the choroid is particularly
high, it would probably remove the drug rapidly from the
interstices into the choroidal vascular bed. Therefore, a sus-
tained administration of an accurate amount of antiangiogenic
substance in an appropriate carrier in the early stage of CNV
would be a major breakthrough. Another application would be
the administration of a growth factor, allowing RPE migration
and proliferation, after surgical removal of subretinal vascular
membranes, to repopulate the excised area. POE was observed
in the suprachoroidal space for approximately 3 weeks, which
means that therapeutic concentrations can theoretically be
maintained in situ during the same period. Indeed, POE under-
goes surface erosion, and drug is released as the polymer
erodes. In vivo results have demonstrated an effective sus-
tained delivery in a model of filtering surgery in the rabbit,17
where 5-fluorouracil was released from POE over 2 weeks at
nontoxic and therapeutic levels to prevent the failure of the
surgery. This 2-week period corresponds to the physical pres-
ence of POE under the conjunctiva.
Among suggested therapeutic approaches in the pharmaco-
logic treatment of neovascularization, the focal delivery of
antiangiogenic drugs to the choroid represents an attractive
possibility. An alternative would be the delivery of drugs that
enhance RPE cell migration and proliferation after surgical
ablation of choroidal neovascular membranes. Such drugs
should be delivered by a sustained-release system, to maintain
therapeutic levels over an extended period. A new therapeutic
approach, based on viscous POE was investigated in the cur-
rent study. Suprachoroidal injection of POE in the rabbit eye
was a feasible and a reproducible procedure for administration.
It was safe and nontraumatic, the risk of infection was limited,
and there was no penetration inside the vitreous cavity or
through the retina.
To ensure that this biomaterial is appropriate for prolonged
administration, repeated surgeries still must be investigated.
The development of POE with a longer lifetime, as well as the
pharmacokinetic determination of the release rate of selected
drugs onto the choroid and the retina are currently under
investigation. These studies also include confirmation of the
tolerance of the formulations, because biocompatibility is case
specific and therefore susceptible to change, depending on
therapeutic entities incorporated in the formulations.
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